Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;57(9):3083-3084.
doi: 10.1007/s11255-025-04514-1. Epub 2025 Apr 17.

Selective factor B inhibition with iptacopan: transforming C3 glomerulopathy management

Matia Fawad Memon  1 , Syed Ibad Hussain  2 , Zauha Fawad Memon  3 , Sibgha Fawad Memon  3
Affiliations

Selective factor B inhibition with iptacopan: transforming C3 glomerulopathy management

Matia Fawad Memon et al. Int Urol Nephrol. 2025 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no competing interests.

References

    1. Nester CM, Eisenberger U, Karras A, le Quintrec M, Lightstone L, Praga M, Remuzzi G, Soler MJ, Liu J, Meier M, Tawfik R, Junge G, Biondani A, Trapani AJ, Webb NJA, Wong EKS (2024) Iptacopan reduces proteinuria and stabilizes kidney function in C3 Glomerulopathy. Kidney Int Rep 10(2):432–446. https://doi.org/10.1016/j.ekir.2024.10.023 - DOI - PubMed - PMC
    1. Wong E, Nester C, Cavero T, Karras A, Le Quintrec M, Lightstone L, Eisenberger U, Soler MJ, Kavanagh D, Daina E, Praga M, Medjeral-Thomas NR, Gäckler A, Garcia-Carro C, Biondani A, Chaperon F, Kulmatycki K, Milojevic J, Webb NJA, Nidamarthy PK, Junge G, Remuzzi G (2023) Efficacy and safety of iptacopan in patients with C3 Glomerulopathy. Kidney Int Rep 8(12):2754–2764. https://doi.org/10.1016/j.ekir.2023.09.017 - DOI - PubMed - PMC
    1. Escudero-Saiz VJ, Gonzalez Á, García-Herrera A, Larque AB, Bomback AS, Morantes L, Martínez-Chillarón M, Ollé J, Guillén E, Xipell M, Molina-Andújar A, Rodríguez D, Cuadrado E, Cacho J, Arana C, Esforzado N, Bastida C, Poch E, Diekman F, Cucchiari D, Quintana LF, Blasco M (2024) Factor B inhibition with iptacopan in recurrent C3 Glomerulopathy following kidney transplant: a report of two cases. Kidney Med 6(6):100823. https://doi.org/10.1016/j.xkme.2024.100823 - DOI - PubMed - PMC
    1. Arnold S, Nickler M, Dickenmann M, Menter T, Hopfer H, Hirt-Minkowski P (2024) First successful treatment of a patient with a primary immune complex-membranoproliferative Glomerulonephritis with iptacopan: a case report. Case Rep Nephrol Dial 14(1):138–147. https://doi.org/10.1159/000540013 - DOI - PubMed - PMC
    1. Bomback AS, Kavanagh D, Vivarelli M, Meier M, Wang Y, Webb NJA, Trapani AJ, Smith RJH (2022) Alternative complement pathway inhibition with iptacopan for the treatment of C3 Glomerulopathy-study design of the APPEAR-C3G trial. Kidney Int Rep 7(10):2150–2159. https://doi.org/10.1016/j.ekir.2022.07.004 - DOI - PubMed - PMC

LinkOut - more resources